Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pozelimab + cemdisiran vs eculizumab/ravulizumab in PNH patients stable on C5 inhibitors
jRCT2031240002Completed
- Sponsor
- Regeneron Pharmaceuticals
- Start
- Jan 2023
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes, Chemically Modified siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
01
Overview
Randomised, open-label trial of pozelimab, cemdisiran, eculizumab and ravulizumab in paroxysmal nocturnal hemoglobinuria (PNH) (2 arms), sponsored by Regeneron Pharmaceuticals. Primary endpoint: Percent change in lactate dehydrogenase (LDH). Started Jan 2023; status: completed.
02
Drugs
pozelimabcemdisiraneculizumabravulizumab
03
Conditions
paroxysmal nocturnal hemoglobinuria (PNH)
Beyond the preview
Go deeper on jRCT2031240002.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031240002.